ELITE PHARMACEUTICALS INC /NV/
ELTPOTCHealthcare · Pharmaceutical Preparations · NJ · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $84.0M | $56.6M | $34.2M | $32.3M | $25.4M | $18.0M |
| Operating income | $19.6M | $10.8M | $3.7M | $5.1M | $2.1M | −$2.3M |
| Net income | −$4.3M | $20.1M | $3.6M | $8.9M | $5.1M | −$2.2M |
| Total assets | $96.4M | $83.7M | $40.9M | $35.1M | $26.2M | $25.0M |
| Total liabilities | $42.9M | $26.1M | $11.9M | $9.9M | $10.0M | $14.3M |
| Equity | $53.5M | $57.6M | $29.0M | $25.2M | $16.2M | $10.7M |
| EPS (diluted) | $0.00 | $0.02 | $0.00 | $0.01 | $0.00 | $0.00 |
| Shares out. | 1.07B | 1.07B | 1.01B | 1.01B | 1.01B | 840.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 23.3%
- Net margin
- −5.1%
- Return on equity
- −8.1%
- Return on assets
- −4.5%
- Return on capital (ROCE)
- 23.2%
- Liabilities / assets
- 44.5%
- Debt / equity
- 0.80×
- Book value / share
- $0.05
- Revenue growth (YoY)
- 48.4%
- Net income growth (YoY)
- −121.5%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 1.72grey zone
- Accruals / assets
- −12.2%clean
- Beneish M-Score
- -2.83normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 5 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Reported a net loss
- Altman Z″ in the grey zone
- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Jun 14, 2019
- NT 10-Kmissed a reporting deadline ↗Jun 15, 2016
- NT 10-Kmissed a reporting deadline ↗Jun 30, 2010
- NT 10-Qmissed a reporting deadline ↗Aug 17, 2009
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Plassche DouglasOfficer — EVP Operations | Jan 9, 2026 | Option exercise | 2.5M | $0.03 |
| Plassche DouglasOfficer — EVP Operations | Oct 2, 2025 | Sell | 800,000 | $0.62 |
| Elite Pharmaceuticals Inc /Nv/Officer — EVP Operations | Aug 22, 2025 | Sell | 500,000 | $0.52 |
| Kirkov KirkoOfficer — Chief Commercial Officer | Jul 10, 2025 | Buy | 16,366 | $0.59 |
| Plassche DouglasOfficer — EVP Operations | Jul 8, 2025 | Sell | 200,000 | $0.58 |
| Plassche DouglasOfficer — EVP Operations | Jul 3, 2025 | Option exercise | 2.5M | $0.03 |
| Plassche DouglasOfficer — SVP of Operations | Oct 23, 2024 | Sell | 800,000 | $0.49 |
| Hakim Nasrat AOfficer — CEO, President | Mar 29, 2024 | Grant | 49.5M | $0.00 |
| Hakim Nasrat AOfficer — CEO, President | Dec 29, 2023 | Grant | 2.2M | $0.07 |
| Whitnell Jeffrey ADirector | Nov 22, 2023 | Grant | 547,657 | $0.04 |
| Caskey Davis SDirector | Nov 22, 2023 | Grant | 547,657 | $0.04 |
| Dash Barry HDirector | Nov 22, 2023 | Grant | 547,657 | $0.04 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.6M | 2.6 | +6.0% |
| Apr 30, 2026 | 2.5M | 2.1 | +1.6% |
| Apr 15, 2026 | 2.4M | 3.6 | -0.6% |
| Mar 31, 2026 | 2.4M | 2.0 | +6.5% |
| Mar 13, 2026 | 2.3M | 1.5 | -6.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureJun 1, 2026
- Regulation FD disclosureApr 2, 2026
- Results of operations · Regulation FD disclosureFeb 17, 2026
- Regulation FD disclosureFeb 11, 2026
- Results of operations · Regulation FD disclosureNov 14, 2025
- Regulation FD disclosureNov 12, 2025
- Regulation FD disclosureNov 10, 2025
- Results of operations · Regulation FD disclosureAug 14, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.